FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107438172> ?p ?o ?g. }

• W2107438172 endingPage "238" @default.
• W2107438172 startingPage "230" @default.
• W2107438172 abstract "To assess objective response rates after 4 cycles of gemcitabine in combination with oxaliplatin in children and adolescents with relapsed or refractory solid tumours.This multicentre, non-randomised Phase II study included five strata: neuroblastoma, osteosarcoma, medulloblastoma and other CNS tumours strata with two-stage Simon designs and a miscellaneous, extra-cranial solid tumour stratum with descriptive design. Eligibility criteria included: age 6 months to 21 years; measurable, relapsed or refractory solid malignancy; no more than one previous salvage therapy. Gemcitabine was administered intravenously at 1000 mg/m(2) over 100 min followed by oxaliplatin at 100mg/m(2) over 120 min on Day 1 of a 14-d cycle. Tumour response was assessed every 4 cycles according to WHO criteria.Ninety-three out of 95 patients enrolled in 25 centres received treatment: 12 neuroblastoma; 12 osteosarcoma; 14 medulloblastoma; 13 other CNS tumours and 42 miscellaneous non-CNS solid tumours. Median age was 11.7 years (range, 1.3-20.8 years). Tumour control (CR+PR+SD) at 4 cycles was obtained in 30/93 evaluable patients (32.3%; 95% confidence interval (CI), 22.9-42.7%), including four PR: 1/12 patients with osteosarcoma, 1/12 with medulloblastoma, 1/12 with rhabdomyosarcoma and 1/4 with other sarcoma. Five out of 12 eligible patients with neuroblastoma experienced stable disease. During a total of 481 treatment cycles (median 4, range 1-24 per patient), the most common treatment-related toxicities were haematologic (leukopenia, neutropenia, thrombocytopenia) and neurological (dysesthesia, paresthesia).The gemcitabine-oxaliplatin combination administered in a bi-weekly schedule has acceptable safety profile with limited activity in children with relapsed or refractory solid tumours." @default.
• W2107438172 created "2016-06-24" @default.
• W2107438172 creator A5000798829 @default.
• W2107438172 creator A5007564466 @default.
• W2107438172 creator A5013232805 @default.
• W2107438172 creator A5018249256 @default.
• W2107438172 creator A5018621362 @default.
• W2107438172 creator A5025577967 @default.
• W2107438172 creator A5027086161 @default.
• W2107438172 creator A5033870647 @default.
• W2107438172 creator A5037782767 @default.
• W2107438172 creator A5040708765 @default.
• W2107438172 creator A5044138253 @default.
• W2107438172 creator A5051922909 @default.
• W2107438172 creator A5062594256 @default.
• W2107438172 creator A5064627114 @default.
• W2107438172 creator A5067202962 @default.
• W2107438172 creator A5080535193 @default.
• W2107438172 creator A5088126168 @default.
• W2107438172 creator A5091190881 @default.
• W2107438172 date "2011-01-01" @default.
• W2107438172 modified "2023-09-27" @default.
• W2107438172 title "Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study" @default.
• W2107438172 cites W1544589523 @default.
• W2107438172 cites W1924785021 @default.
• W2107438172 cites W1985101533 @default.
• W2107438172 cites W1988305907 @default.
• W2107438172 cites W1989713903 @default.
• W2107438172 cites W1999532427 @default.
• W2107438172 cites W2004787353 @default.
• W2107438172 cites W2032806260 @default.
• W2107438172 cites W2049141908 @default.
• W2107438172 cites W2050014629 @default.
• W2107438172 cites W2053552326 @default.
• W2107438172 cites W2062166876 @default.
• W2107438172 cites W2081556301 @default.
• W2107438172 cites W2082598176 @default.
• W2107438172 cites W2087667095 @default.
• W2107438172 cites W2091323340 @default.
• W2107438172 cites W2096398040 @default.
• W2107438172 cites W2096888043 @default.
• W2107438172 cites W2097642908 @default.
• W2107438172 cites W2101310161 @default.
• W2107438172 cites W2102925522 @default.
• W2107438172 cites W2105821373 @default.
• W2107438172 cites W2121368761 @default.
• W2107438172 cites W2130017050 @default.
• W2107438172 cites W2132865716 @default.
• W2107438172 cites W2151322055 @default.
• W2107438172 cites W2152960203 @default.
• W2107438172 cites W2160509211 @default.
• W2107438172 cites W2161254114 @default.
• W2107438172 cites W2163261709 @default.
• W2107438172 cites W2166574172 @default.
• W2107438172 cites W2167805334 @default.
• W2107438172 cites W2170780843 @default.
• W2107438172 doi "https://doi.org/10.1016/j.ejca.2010.09.015" @default.
• W2107438172 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20943374" @default.
• W2107438172 hasPublicationYear "2011" @default.
• W2107438172 type Work @default.
• W2107438172 sameAs 2107438172 @default.
• W2107438172 citedByCount "39" @default.
• W2107438172 countsByYear W21074381722012 @default.
• W2107438172 countsByYear W21074381722013 @default.
• W2107438172 countsByYear W21074381722014 @default.
• W2107438172 countsByYear W21074381722015 @default.
• W2107438172 countsByYear W21074381722016 @default.
• W2107438172 countsByYear W21074381722017 @default.
• W2107438172 countsByYear W21074381722018 @default.
• W2107438172 countsByYear W21074381722019 @default.
• W2107438172 countsByYear W21074381722020 @default.
• W2107438172 countsByYear W21074381722021 @default.
• W2107438172 countsByYear W21074381722022 @default.
• W2107438172 countsByYear W21074381722023 @default.
• W2107438172 crossrefType "journal-article" @default.
• W2107438172 hasAuthorship W2107438172A5000798829 @default.
• W2107438172 hasAuthorship W2107438172A5007564466 @default.
• W2107438172 hasAuthorship W2107438172A5013232805 @default.
• W2107438172 hasAuthorship W2107438172A5018249256 @default.
• W2107438172 hasAuthorship W2107438172A5018621362 @default.
• W2107438172 hasAuthorship W2107438172A5025577967 @default.
• W2107438172 hasAuthorship W2107438172A5027086161 @default.
• W2107438172 hasAuthorship W2107438172A5033870647 @default.
• W2107438172 hasAuthorship W2107438172A5037782767 @default.
• W2107438172 hasAuthorship W2107438172A5040708765 @default.
• W2107438172 hasAuthorship W2107438172A5044138253 @default.
• W2107438172 hasAuthorship W2107438172A5051922909 @default.
• W2107438172 hasAuthorship W2107438172A5062594256 @default.
• W2107438172 hasAuthorship W2107438172A5064627114 @default.
• W2107438172 hasAuthorship W2107438172A5067202962 @default.
• W2107438172 hasAuthorship W2107438172A5080535193 @default.
• W2107438172 hasAuthorship W2107438172A5088126168 @default.
• W2107438172 hasAuthorship W2107438172A5091190881 @default.
• W2107438172 hasConcept C121608353 @default.
• W2107438172 hasConcept C126322002 @default.
• W2107438172 hasConcept C141071460 @default.
• W2107438172 hasConcept C142724271 @default.
• W2107438172 hasConcept C143998085 @default.

• next